BG Medicine, Inc.
DelistedCIK 1407038fmd_15WY3QW35F4D1AZPRZP2F9YHF6Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2015, 24 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 1 | 2 | 3 | 4 | 3 | 2 |
| Cost of revenue | 8 | 0 | 0 | 1 | 1 | 1 | 1 |
| Gross profit | 0 | 1 | 1 | 2 | 3 | 2 | 1 |
| Research and development | 9 | 7 | 8 | 8 | 4 | 2 | 2 |
| Selling, general and administrative | 8 | 8 | 11 | 17 | 13 | 7 | 4 |
| Operating income | (16) | (15) | (17) | (23) | (14) | (7) | (5) |
| Interest expense | 0 | 3 | 0 | 1 | 1 | 1 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | (0) | 0 | (0) | 0 | 0 | 0 | (1) |
| Net income | (17) | (18) | (18) | (24) | (16) | (8) | (5) |
| Net income to common shareholders | – | – | (18) | (24) | (16) | (8) | (7) |